You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

CLINICAL TRIALS PROFILE FOR ABILIFY

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ABILIFY

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00044655 ↗	Switching Medication to Treat Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2001-07-01	This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 ↗	Switching Medication to Treat Schizophrenia	Completed	Icahn School of Medicine at Mount Sinai	Phase 4	2001-07-01	This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00080314 ↗	Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode	Completed	Otsuka America Pharmaceutical	Phase 3	2004-01-01	The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
NCT00080314 ↗	Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3	2004-01-01	The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ABILIFY

Condition Name

Chart
Table

Condition Name for ABILIFY
Intervention	Trials
Schizophrenia	61
Bipolar Disorder	25
Major Depressive Disorder	16
Schizoaffective Disorder	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ABILIFY
Intervention	Trials
Schizophrenia	63
Disease	52
Bipolar Disorder	28
Depression	27
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ABILIFY

Trials by Country

Map
Table

Trials by Country for ABILIFY
Location	Trials
United States	592
Canada	26
United Kingdom	21
Korea, Republic of	18
Spain	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ABILIFY
Location	Trials
California	41
New York	40
Texas	33
Ohio	29
Florida	28
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ABILIFY

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ABILIFY
Clinical Trial Phase	Trials
Phase 4	67
Phase 3	44
Phase 2/Phase 3	1
[disabled in preview]	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ABILIFY
Clinical Trial Phase	Trials
Completed	123
Terminated	15
Recruiting	7
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ABILIFY

Sponsor Name

Chart
Table

Sponsor Name for ABILIFY
Sponsor	Trials
Otsuka Pharmaceutical Development & Commercialization, Inc.	41
Bristol-Myers Squibb	30
Otsuka America Pharmaceutical	28
[disabled in preview]	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ABILIFY
Sponsor	Trials
Other	140
Industry	128
NIH	22
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.